Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2023-182345

Published: 2023

Journal Articles

Treatment Outcomes for Adults with Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study

Jennifer J. Huang, Jacob S. Appelbaum, Kathryn Russell, Carole Shaw, Ashley M. Eckel, Xueyan Chen, Rutu D. Vyas, Paul C. Hendrie, Anna B. Halpern, Raya Mawad, Ryan D Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival, Cristina Maria Ghiuzeli

Blood (2023) 142 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2023-188461

Published: 2023

Journal Articles

Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3765–3766.

https://doi.org/10.1182/blood-2022-164823

Published: 2022

Journal Articles

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Blood (2022) 140 (Supplement 1): 10140–10141.

https://doi.org/10.1182/blood-2022-159969

Published: 2022

Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan

Blood (2022) 140 (Supplement 1): 7284–7285.

https://doi.org/10.1182/blood-2022-159665

Published: 2022

Journal Articles

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, Gautam Borthakur, Brian Ball, Harry P. Erba, Raya Mawad, Marina Kremyanskaya, James S. Blachly, Hetty E. Carraway, Ahrim Youn, Jessica Garzon, Daniel Lopes de Menezes, Patricia Martin-Regueira, C.L. Beach, Justin Watts

Blood (2021) 138 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2021-146791

Published: 2021

Journal Articles

Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, Tenzin Tsomo, Tori Braun, Jennie Szeto, William I. Bensinger, Daniel Egan, Raya Mawad, Livia Hegerova, Gayle Funk, Joanna Fesler, Sonia Glennie, Judson Hall, Vanessa Dunleavy, Heidi Hohmann, Jordan Briggs, Joshua Mark, Megumi Bailey, John M. Pagel, Krish Patel

Blood (2021) 138 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2021-148505

Published: 2021

Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Blood (2021) 138 (1): 11–22.

https://doi.org/10.1182/blood.2020009098

Published: 2021

Includes: Supplemental data

Journal Articles

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, MSc, Tenzin Tsomo, BS, Jennie Szeto, BA, William I Bensinger, MD, Daniel Egan, MD, Livia Hegerova, MD, Raya Mawad, MD, Ami Batchelder, PA, Joanna Fesler, ARNP, Heather Holdread, MS,NP, Sonia Glennie, ARNP, Judson Hall, ARNP, Joey Ferry, ARNP, Megumi Bailey, MSc, David Kane, RN, John M. Pagel, MDPhD, Krish Patel, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141074

Published: 2020

Journal Articles

The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative

Joseph F. Ferry, Neil Bailey, MSc, Vanessa Dunleavy, ARNP, Joanna Fesler, ARNP, Judson Hall, PA-C, Sonia Glennie, ARNP, William I Bensinger, MD, Raya Mawad, MD, Krish Patel, MD, Daniel Egan, MD, John M. Pagel, MDPhD, Livia Hegerova, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-143299

Published: 2020

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi, MBBS, Asad Bashey, MD PhD, Wendy Stock, MD, James M. Foran, MD, Raya Mawad, MD, Daniel Egan, MD, William Blum, MD, Allen Yang, MD PhD, Alessandro Pastore, MD, Chelsea Johnson, BSN,RN, Shuo Zheng, Musa Yilmaz, MD, Alice S. Mims, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134746

Published: 2020

Journal Articles

A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes

Neil Bailey, MSc, John M. Pagel, MD PhD, William Bensinger, MD, Livia Hegerova, MD, Raya Mawad, MD, Michael Milder, MD, Jennie Szeto, BA, Ngan Trinh, BS, Tenzin Tsomo, BS, Paul Wisniewski, BS, Clarisse M. Zayas, Krish Patel, MD

Blood (2018) 132 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2018-99-117780

Published: 2018

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 763.

https://doi.org/10.1182/blood-2018-99-119786

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Mazyar Shadman, MD MPH, Ajay K Gopal, MD, Oliver Press, MD PhD, David G. Maloney, MD PhD, Raya Mawad, MD, Troy Wadsworth, MD, Trevor W. Dennie, MD, Karl Schultheiss, MD, Kiarash Kojouri, MD MPH, Britt E Kammerer, John M. Pagel, MD PhD

Blood (2016) 128 (22): 4396.

https://doi.org/10.1182/blood.V128.22.4396.4396

Published: 2016

Journal Articles

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment

Johnnie J. Orozco, Aimee Kenoyer, Ethan R. Balkin, Ted A. Gooley, Donald K. Hamlin, D. Scott Wilbur, Mark D. Hylarides, Sofia H. L. Frost, Raya Mawad, Paul O’Donnell, Brenda M. Sandmaier, Ephraim J. Fuchs, Leo Luznik, Damian J. Green, Ajay K. Gopal, Oliver W. Press, John M. Pagel

Blood (2016) 127 (3): 352–359.

https://doi.org/10.1182/blood-2014-12-617019

Published: 2016

Includes: Supplemental data

Journal Articles

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Mazyar Shadman, MD MPH, Raya Mawad, MD, Carol Dean, MPH, BSN, Kathleen Shannon-Dorcy, RN,PhD, Vicky Sandhu, MD MPH, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, John Pagel, MD PhD, Elihu H. Estey, MD

Blood (2014) 124 (21): 3732.

https://doi.org/10.1182/blood.V124.21.3732.3732

Published: 2014

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

NARROW

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Treatment Outcomes for Adults with Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study

Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only